(Q34090973)

30 July 2017

1 reference

title

Novel strategies for systemic treatment of endometrial cancer (English)

1 reference

30 July 2017

Elit L

1

1 reference

30 July 2017

Hirte H

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

12

1 reference

30 July 2017

page(s)

2831-2853

1 reference

Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Adjuvant chemotherapy for high-risk endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Oncogene alterations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Independent prognostic importance of microvessel density in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Matrix metalloproteinases and their inhibitors in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Hydroxyprogesterone caproate therapy in advanced endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Endometrial cancer: Approach to development of effective chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Perspectives on research in gynecologic oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the grupo ginecologico Español para el tratamiento oncologico (GGETO)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2831

10.1517/13543784.9.12.2831

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference